Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

威尼斯人 阿扎胞苷 克拉屈滨 医学 髓系白血病 阿糖胞苷 内科学 癸他滨 低甲基化剂 肿瘤科 白血病 慢性淋巴细胞白血病 DNA甲基化 化学 基因表达 基因 生物化学
作者
Patrick K. Reville,Hagop Kantarjian,Gautam Borthakur,Naveen Pemmaraju,Naval Daver,Courtney D. DiNardo,Koji Sasaki,Nicholas J. Short,Ghayas C. Issa,Maro Ohanian,Elias Jabbour,Guillermo Montalban‐Bravo,Abhishek Maiti,Nitin Jain,Alessandra Ferrajoli,Kapil N. Bhalla,Koichi Takahashi,Caitlin R. Rausch,Danielle Hammond,Rashmi Malla,Kelly Quagliato,Mark Brandt,Uday Popat,Marina Konopleva,Guillermo Garcia‐Manero,Farhad Ravandi,Tapan M. Kadia
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 9041-9043 被引量:2
标识
DOI:10.1182/blood-2022-168029
摘要

Background The combination of venetoclax with AZA for patients with newly diagnosed AML who are older or unfit for intensive chemotherapy significantly improves remission rates and survival compared to AZA alone. A low-intensity backbone combining venetoclax with cladribine (CLAD) plus low-dose araC (LDAC) alternating with HMA has demonstrated encouraging results in older patients with newly diagnosed AML (Kadia TM, et al. J Clin Oncol. 2022). Here we report an updated cohort of patients with longer-term follow up treated on the phase 2 clinical trial of venetoclax added to CLAD/LDAC alternating with AZA. Methods This is a phase 2 study (NCT03586609) investigating the combination of venetoclax with CLAD/LDAC alternating with AZA in older (age ≥ 60 years) or patients <60 years that are unfit for intensive chemotherapy with newly diagnosed AML (excluding APL, CBF). The primary objective was composite complete response rate (CRc; CR+CRi); secondary endpoints were overall survival (OS), disease-free survival (DFS), overall response rate (ORR), and toxicity. Induction was with cladribine 5 mg/m2 IV on D1-5 and araC 20mg SQ BID on D1-10. Consolidation/maintenance consisted of 2 courses of cladribine 5 mg/m2 IV on D1-3 and araC 20 mg SQ BID on D1-10 alternating with 2 cycles of AZA 75 mg/m2 on D1-7, for up to 18 courses. Venetoclax 400 mg was added for each course with dose adjustments for concomitant CYP3A inhibitors. Venetoclax was given for 21 days during induction and for 7-14 days for consolidation depending on measurable residual disease (MRD) and tolerability. One cycle was 4 weeks and up to 2 cycles of induction were allowed. Results A total of 93 patients were treated on study with a median age was 68 years (range: 57 - 84); 28 (30%) patients were ≥ 70 yrs and 1 patient <60, unfit for intensive chemotherapy was enrolled. 29 (31%) patients had secondary or therapy related AML. 52 (56%) had diploid cytogenetics with 11 (12%) having adverse cytogenetics at enrollment. By European Leukemia Network (ELN) risk, 24%, 24%, and 53% were favorable, intermediate, and adverse risk, respectively. The most commonly mutated genes were DNMT3A in 28 (30%), NPM1 in 26 (28%), RAS in 23 (25%), TET2 in 22 (24%), and IDH2 in 20 (22%). TP53 was mutated in 8 (9%) patients. Among 93 evaluable patients the CRc rate was 92%. Best response was CR in 72 (78%), CRi in 13 (14%), no response in 5 (5%), and death in 2 (2%) patients. In responding patients with a bone marrow sample evaluable for assessment of MRD by flow cytometry, 71/85 (84%) achieved MRD negativity while on study. Responses were preserved across ELN risk groups with the CRc (CR/CRi) rate of 95% (86%/9%), 95% (82%/14%), and 90% (73%/17%) for patients with ELN favorable, intermediate, and adverse risk, respectively. CRc rate for TP53 mutated disease was 88% (7/8, 86% MRD negative) and for NPM1 mutated disease was 96% (25/26, 100% MRD negative). 35 (41%) responders received a subsequent allogeneic stem cell transplantation (alloSCT). Early mortality was low with two patients (2%) dying within 4 weeks and five patients (5%) dying with in 8 weeks. The most frequent grade 3/4 non-heme adverse events were febrile neutropenia (n=12), infection (n=7), atrial fibrillation (n=2), and allergic reaction (n=2). One patient developed grade 4 tumor lysis syndrome. With a median follow up of 22.8 months, the median duration of response (DOR) is not reached (95% CI: NE - NE months). Estimated 12- and 24-month DOR are 88.4% (95% CI: 81.0 - 96.4%) and 81.0% (95% CI: 71.0 - 92.4%), respectively. Median disease-free survival (DFS) is not yet reached (95% CI: 24.5 - NE months). Estimated 12- and 24-month DFS are 76.0% (95% CI: 66.8 - 86.4%) and 63.4% (95% CI: 52.1 - 77.1%), respectively. Median overall survival (OS) is not yet reached (95% CI: 25.4 - NE months). Estimated 12- and 24-month OS are 75.7% (95% CI: 66.9 - 85.7%) and 68.3% (95% CI: 58.1 - 80.1%), respectively (Figure). Conclusion Venetoclax added to CLAD/LDAC alternating with AZA is a highly effective, lower-intensity regimen which is well tolerated among older patients with newly diagnosed AML, producing high CRc and MRD negative remission rates and is effective in transitioning older adults to alloSCT. The rates of DFS and OS are encouraging. Further study of this non-anthracycline containing regimen is warranted in older patients both fit and unfit for intensive chemotherapy as a safe and effective induction treatment strategy. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拳拳发布了新的文献求助10
刚刚
刚刚
zz完成签到,获得积分10
刚刚
GIN的应助被王艳采纳,获得20
1秒前
1秒前
FashionBoy的应助被毛豆爱睡觉采纳,获得10
2秒前
酷酷的南莲完成签到,获得积分10
2秒前
2秒前
3秒前
4秒前
5秒前
ZZ发布了新的文献求助10
6秒前
丘比特的应助被牛马大帝采纳,获得10
6秒前
7秒前
7秒前
Organic123发布了新的文献求助10
7秒前
科研小白完成签到 ,获得积分10
7秒前
7秒前
Ali完成签到,获得积分10
8秒前
优美小海豚完成签到,获得积分10
8秒前
Nihai发布了新的文献求助10
9秒前
科研通AI2S的应助被zc采纳,获得10
9秒前
小马甲的应助被zxhkplio采纳,获得10
9秒前
赘婿的应助被richardhipower采纳,获得10
9秒前
维多利亚发布了新的文献求助10
10秒前
pyridine完成签到,获得积分10
10秒前
cdercder的应助被Lydia采纳,获得10
10秒前
123完成签到,获得积分10
11秒前
高贵白凝发布了新的文献求助10
11秒前
11秒前
JamesPei的应助被ZZ采纳,获得10
12秒前
12秒前
zww发布了新的文献求助10
12秒前
Nole的应助被一切都好采纳,获得10
14秒前
Nole的应助被Xiiiii9采纳,获得10
14秒前
bkagyin的应助被高锰酸钾采纳,获得10
14秒前
aajhajkahna的应助被火山采纳,获得10
15秒前
要减肥的访旋完成签到,获得积分10
15秒前
流年完成签到 ,获得积分10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192604
求助须知:如何正确求助?哪些是违规求助? 9579105
关于积分的说明 21863529
捐赠科研通 7792211
什么是DOI,文献DOI怎么找? 3436974
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864